Caitlin Fowler took on a lofty charity challenge to go the distance for partner Lucy Stewart who has a rare lifechanging auto ...

Myasthenia gravis affects about 30 out of every 100,000 people in Canada, according to the Myasthenia Gravis Society of ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an ...

UCB, a global biopharmaceutical company, today announced the recipients of its annual UCB Myasthenia Gravis Scholarship,™ awarding 15 scholarships to individuals in the United States who are living ...

Vor Biopharma pivots to telitacicept for autoimmune diseases, backed by $491M cash to 2029. Click here to read an analysis of ...

Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by ...

ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of ...

J&J presents new Imaavy data at EAN 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis: Geneva Monday, June 29, 2026, 18:00 Hrs [IST] Johnson & J ...

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...

New analyses from the Phase 3 Vivacity-MG3 study support the impact of nipocalimab in anti-AChR+a, anti-MuSK+b adult patients with generalised myasthenia gravis (gMG) including those early in their ...

Johnson & Johnson (NYSE: JNJ) today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY® ...

Discover practical, expert-recommended home modifications that can help reduce fatigue and prevent injury in people living ...